Claudin 18 (43–14A clone) expression in pancreatic ductal adenocarcinoma: Assessment of a potential clinical biomarker for zolbetuximab therapy

Claudin 18 (43–14A clone) expression in pancreatic ductal adenocarcinoma: Assessment of a potential clinical biomarker for zolbetuximab therapy

Pancreatic ductal adenocarcinoma (PDAC) remains highly lethal, with a five-year survival rate below 15 %. Claudin 18.2 (CLDN18.2) has emerged as a novel potential therapeutic target in PDAC. Zolbetuximab, a monoclonal antibody targeting CLDN18.2, has demonstrated therapeutic benefit in gastric cance...

Full description

Saved in:
Bibliographic Details
Main Authors: Riley J. Arseneau, Emma Kempster, Carley Bekkers, Thomas Samson, Boris L. Gala-Lopez, Ravi Ramjeesingh, Jeanette E. Boudreau, Thomas Arnason
Format: Article
Language:English
Published: Elsevier 2025-05-01
Series:Translational Oncology
Subjects:
Pancreatic ductal carcinoma
Immunohistochemistry
Claudin 18 protein, human
Biomarkers
43–14a
zolbetuximab
Online Access:http://www.sciencedirect.com/science/article/pii/S1936523325000932
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://www.sciencedirect.com/science/article/pii/S1936523325000932

Similar Items